SAN MATEO, Calif. (AP) ¿ Biotechnology company NeurogesX Inc. said Monday it received Food and Drug Administration approval for its Qutenza pain patch. The regulatory approval is for postherpetic neuralgia, a type of nerve pain condition that results from shingles. The patch is already approved in Europe for peripheral nerve pain in non-diabetic adults. NeurogesX plans to launch Qutenza in the United States through its own sales force in the first half of 2010. Shares of NeurogesX rose 76 cents, or 9.2 percent, to $9 in after-hours trading after falling 4 cents to close at $8.24 during the regular trading session.